CTA-PB — EIDP, Inc. USD 4.50 Cum Pfd Registered Shs

Corteva Agriscience Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Performance: Organic sales decreased by 4% year-over-year, with Crop Protection volumes down 2% and prices down 1%. Seed pricing increased by 3%, but volumes fell by 8% due to timing shifts.
• Full Year Performance: Organic sales increased by 4%, with operating EBITDA up 14% to $3.85 billion, achieving an operating EBITDA margin of over 22%, a 215 basis point improvement.
• Free Cash Flow: Improved significantly to $2.9 billion, up $1.2 billion from the previous year, driven by higher earnings and working capital discipline.

2. Strategic Updates and Business Highlights

• Separation Update: Corteva is on track for a corporate separation in Q4 2026, with a new CEO search underway and plans to announce leadership teams and brand identity for the new entity.
• Bayer Agreement: A comprehensive resolution with Bayer enhances Corteva's licensing capabilities, allowing for earlier introduction of proprietary technologies and entry into the cotton market. Expected to generate approximately $1 billion in earnings upside over the next decade.
• Seed Business: Achieved organic growth across all regions, with significant cost improvements and share gains in corn and soybeans. Anticipated to cross double-digit trade penetration for Conkesta in Brazil.
• Crop Protection: Despite challenging market conditions, the business delivered growth and margin expansion, supported by a $9 billion pipeline of differentiated technologies.

3. Forward Guidance and Outlook

• 2026 Guidance: Operating EBITDA expected to be between $4.0 billion and $4.2 billion, representing a 7% growth at the midpoint. Operating EPS projected in the range of $3.45 to $3.70 per share.
• Market Expectations: Anticipated modest growth in Crop Protection, with pricing pressures expected to continue. Seed volumes expected to remain flat due to shifts in crop acreage.
• Productivity Improvements: Targeting $200 million in productivity savings for 2026, with a focus on cost management and operational efficiency.

4. Bad News, Challenges, or Points of Concern

• Q4 Declines: The fourth quarter saw declines in both sales and operating EBITDA compared to the previous year, largely due to lower volumes and increased compensation expenses.
• Competitive Pricing Pressures: Ongoing competitive pricing dynamics, particularly in Latin America and Asia Pacific, are expected to impact Crop Protection pricing.
• Farmer Financial Stress: High interest rates and suppressed commodity prices are creating cash flow challenges for farmers, potentially affecting their purchasing behavior.
• Tariff Impacts: An estimated $80 million headwind from tariffs is anticipated in 2026, which could affect overall profitability.

5. Notable Q&A Insights

• Bayer Agreement Details: The agreement enhances Corteva's licensing strategy, allowing for earlier market entry of key products and resolving litigation issues with Bayer.
• Gene Editing Developments: Positive regulatory developments in Europe may open markets for gene-edited seeds, with Corteva's multi-disease resistant corn expected to be commercialized within 1-2 years post-approval.
• Order Book Strength: Strong order books in both Seed and Crop Protection indicate a solid start to 2026, although shifts in crop acreage may impact Seed volumes.
• Market Conditions in Brazil: The Crop Protection market in Brazil remains well-supplied, with pricing pressures expected to persist, but demand for differentiated products continues to be strong.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by Corteva Agriscience as discussed in the Q4 2025 earnings call.